Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$221 Mln
P/E Ratio
--
P/B Ratio
1.44
Industry P/E
--
Debt to Equity
0.47
ROE
-0.85 %
ROCE
-62.04 %
Div. Yield
0 %
Book Value
2.84
EPS
-3.32
CFO
$-728.22 Mln
EBITDA
$-1,106.09 Mln
Net Profit
$-1,127.64 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| -57.69 | 37.58 | -44.16 | 28.35 | -10.33 | -39.66 | -- |
|
BSE Sensex*
| 2.75 | 3.85 | 5.92 | 9.04 | 11.81 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| 224.15 | -57.54 | -91.55 | -42.29 | 104.18 | 913.38 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular... endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Address: 1200 Page Mill Road, Palo Alto, CA, United States, 94304 Read more
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kodiak Sciences Inc (KOD) stood at $ 336 Mln as on 31-Dec-24
The share price of Kodiak Sciences Inc (KOD) is $4.21 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Kodiak Sciences Inc (KOD) has given a return of -10.33% in the last 3 years.
Kodiak Sciences Inc (KOD) has a market capitalisation of $ 221 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Kodiak Sciences Inc (KOD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kodiak Sciences Inc (KOD) and enter the required number of quantities and click on buy to purchase the shares of Kodiak Sciences Inc (KOD).
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Address: 1200 Page Mill Road, Palo Alto, CA, United States, 94304
The CEO & director of Dr. Victor Perlroth M.D.. is Kodiak Sciences Inc (KOD), and CFO & Sr. VP is Dr. Victor Perlroth M.D..
There is no promoter pledging in Kodiak Sciences Inc (KOD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Kodiak Sciences Inc (KOD) | Ratios |
|---|---|
|
Return on equity(%)
|
-84.7
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kodiak Sciences Inc (KOD) was $0 Mln.
$0.10
(
